Arca
Skip to content
Tools
Tools

Renal cell carcinoma metastatic

Drug research and approvals for renal cell carcinoma metastatic: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 136 studies of renal cell carcinoma metastatic are recruiting on ClinicalTrials.gov, and Health Canada has authorized 15 drug trials for it since 2013.

  • Recruiting worldwide: 136
  • Trials authorized in Canada: 15
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 136 recruiting on ClinicalTrials.gov ↗

How its trials ended

1,781 ClinicalTrials.gov studies of renal cell carcinoma in general, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 527 whose ending is known, 28% met their primary endpoint, 11% missed it and 61% stopped early.

  • Completed, result not reported62235%
  • Ongoing46926%
  • Status unknown1639%
  • Stopped: other or unclear1478%
  • Met its primary endpoint1468%
  • Stopped: enrollment or feasibility865%
  • Missed its primary endpoint573%
  • Stopped: sponsor or business decision432%
  • Stopped: lack of efficacy282%
  • Stopped: funding141%
  • Stopped: safety6<1%

Trials authorized in Canada

The 10 newest of 15; search them all in Canada trials
Dec 21, 2020A phase 2, single-arm, open-label clinical trial of pembrolizumab plus lenvatinib in participants with first line advanced/metastatic non-clear cell renal cell…Pembrolizumab/ LenvatinibMerck & Co. (MSD)Ongoing
Dec 14, 2017A randomized, open-label, phase 3 study to evaluate efficacy and safety of pembrolizumab (MK-3475) plus epacadostat vs standard of care (sunitinib or…Pembrolizumab (MK-3475) / Epacadostat (INCB024360)IncyteClosed
Aug 8, 2016A phase III randomized, open-label study to evaluate efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy…Keytruda / AxitinibMerck & Co. (MSD)Ongoing
Jul 27, 2016A randomized, phase II efficacy assessment of multiple met kinase inhibitors (cabozantinib [nsc #761968], crizotinib [nsc #749005], savolitinib [nsc #785348],…Cabozantinib/ Crizotinib/ Savolitinib/ SunitinibCanadian Cancer Trials Group, Cancer Research Institute, Queen's UniversityClosed
Apr 13, 2016A phase 2, open-label study to evaluate the efficacy and safety of single-agent MLN0128 and the combination of MLN0128+MLN1117 compared with everolimus in the…Serabelisib (MLN1117)/ Sapanisertib (MLN0128)/ EverolimusTakeda Pharmaceuticals USAClosed
Mar 9, 2016A phase 1/1b, open-label, multicenter, repeat-dose, dose-selection study of CPI-444 as single agent and in combination with atezolizumab in patients with…Ciforadenant (CPI-444) / AtezolizumabCorvus PharmaceuticalsClosed
Feb 12, 2016A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride (AV-951) to sorafenib in subjects with refractory advanced…Tivozanib (AV-951)LG ChemClosed
Feb 4, 2016A phase 3, multinational, randomized, open-label, parallel-arm study of avelumab (MSB0010718C) in combination with axitinib (INLYTA) versus sunitinib (SUTENT)…MSB0010718C (avelumab) / Axitinib / SunitinibPfizerOngoing
Nov 27, 2015A multi-center, open label, randomized phase 2 study of AGS-16C3F vs axitinib in metastatic renal cell carcinomaAGS-16C3F / AxitinibAstellas PharmaOngoing
Apr 9, 2015A phase III, open-label, randomized study of MPDL3280A (anti-PD-L1 antibody) in combination with bevacizumab versus sunitinib in patients with untreated…RO5541267 (MPDL3280A, atezolizumab) / Bevacizumab / Fludeoxyglucose 18F /…RocheOngoing

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.